retatrutide ly3437943 clinical trial A Study of (LY3437943) in Participants Who Have Obesity or Overweight and Chronic Low Back Pain (TRIUMPH-7) Triple hormone receptor agonist retatrutide
Description
The TRIUMPH-4 Phase 3 trial showed retatrutide reduced knee pain by 75.8% in participants with obesity and osteoarthritis a finding that reframes this peptide as a joint health therapy, not just a weight loss drug.
Refrigerator-Friendly Case Can be stored in the fridge to keep your vials cool, helping preserve medication safely
The mean weight loss among patients prescribed GLP-1 analogue monotherapy at 12 months was 11.42kg, SD 9.95 (9.6% TBWL)
Regence Weight Loss Medication Coverage 2024 | Eligible Prescriptions, Copays, and Prior Authorization
Finally, the desire to eat any type of food was decreased by exogenous administrated GLP-1.
